In the area of breast cancer treatment, immunization treatment, as an emerging and highly promising treatment method, is gradually changing the treatment pattern for breast cancer, giving new hope to many patients.
Our immune system is like the body’s “guardian” and is always alert to alien pathogens and attacks on abnormal cells in the body. Under normal circumstances, the immune system can identify and remove tumor cells. However, sly tumour cells can develop a number of escape mechanisms that make the immune system ineffective.
The core principle of immunisation treatment for breast cancer is to enhance the ability of immunosuppressive cells to recognize and attack breast cancer cells by using drugs to activate their own immune system and to break the immunity escape from tumours. Among them, an important immunotherapy drug is an immunosuppressant. When our immune system works, there are “checkpoints”, which are like “brakes” of the immune system, preventing excesses of the immune cell and the wrong injury to normal cells. But tumor cells can use these “brakes” to shield themselves from the immune system. The effect of the immunosuppressants is to release these “brakes” so that the immunosuppressants can be re-energized and free from breast cancer.
Immunization treatment has a unique advantage over traditional breast cancer treatment. Traditional surgical treatment is based on the direct removal of tumour tissue; chemotherapy is the use of chemical drugs to kill cancer cells, but at the same time it can cause greater damage to normal cells; and the release is the destruction of the DNA of cancer cells by radiation. Immunotherapy, on the other hand, is directed at the human immune system, which stimulates the patient ‘ s own anti-oncological immune response, with special characteristics and relatively small side effects. Moreover, if immunisation treatment works, it may produce long-term immune memory and inhibit the recurrence and growth of tumours over a period of time.
However, immunization against breast cancer does not apply to all patients. Current research has found that immunisation treatment may have better results for certain specific types of breast cancer, such as triple-negative breast cancer. This is because triple-negative breast cancer cells have more abnormal antigens that can be identified by the immune system and are more likely to trigger an immune response. But even for these relatively sensitive breast cancer types, immunization treatment is not 100 per cent effective. Doctors determine the suitability of patients for immunisation and the development of individualized treatments, taking into account the multiple factors of the patient ‘ s breast cancer stratification, stratification, genetic test results and physical condition.
Patients may have some adverse effects during their immunization treatment. Fragile, rash, diarrhoeal, thyroid abnormalities are common. Most of these adverse effects are light to moderate and can generally be effectively controlled through appropriate drug treatment or treatment. However, there are also a small number of patients who are likely to have more serious immunization-related adverse effects, such as immuno-pneumonia and hepatitis, which require close monitoring of the patient ‘ s physical condition and timely adjustment of treatment programmes.
Breast cancer immunization provides new treatment options and hope for breast cancer patients. It uses the human body ‘ s own immune system to combat cancer, complementing traditional treatments and providing additional opportunities for breast cancer patients at different stages and types to overcome diseases. With further medical research and technological advances, it is believed that immunization against breast cancer will play a greater role in the future, allowing more patients to benefit from this innovative treatment and to embrace a healthy life.
